Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 20.08 AUD 1.67% Market Closed
Market Cap: 2.5B AUD

Neuren Pharmaceuticals Ltd
Accounts Payable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Neuren Pharmaceuticals Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Neuren Pharmaceuticals Ltd
ASX:NEU
Accounts Payable
AU$6.7m
CAGR 3-Years
83%
CAGR 5-Years
62%
CAGR 10-Years
7%
Recce Pharmaceuticals Ltd
ASX:RCE
Accounts Payable
AU$2.7m
CAGR 3-Years
77%
CAGR 5-Years
76%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Accounts Payable
AU$30.3m
CAGR 3-Years
-22%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Accounts Payable
AU$11.7m
CAGR 3-Years
36%
CAGR 5-Years
63%
CAGR 10-Years
67%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Accounts Payable
AU$3.2m
CAGR 3-Years
4%
CAGR 5-Years
83%
CAGR 10-Years
N/A
Nyrada Inc
ASX:NYR
Accounts Payable
AU$1.5m
CAGR 3-Years
183%
CAGR 5-Years
22%
CAGR 10-Years
N/A
No Stocks Found

Neuren Pharmaceuticals Ltd
Glance View

Market Cap
2.5B AUD
Industry
Pharmaceuticals

Founded in 1993, Neuren Pharmaceuticals Ltd has carved a niche for itself within the biotech industry, focusing primarily on neurological and neurodevelopmental disorders. The company operates at the intriguing intersection of innovation and medicine, where the stakes are high, but so are the potential rewards. Neuren has its headquarters in Australia and has oriented its research towards developing therapies that could change the lives of those affected by conditions like Rett syndrome and Fragile X syndrome. By adopting a strategic approach that combines cutting-edge science with a relentless focus on unmet needs, Neuren positions itself uniquely through its proprietary compounds such as trofinetide and NNZ-2591, which are at the core of its research endeavors. The company's business model hinges on a dual approach: developing its own drugs while simultaneously fostering partnerships with larger pharmaceutical companies to bring these therapies to market. This model allows Neuren to share the substantial costs and risks inherent in drug development while benefiting from the expanse of its partners' distribution networks and market insights. Revenue generation kicks in primarily through milestone payments, royalties, and licensing agreements as these partners help navigate the rigorous phases of clinical trials and regulatory approvals. Financial stability is thus intricately tied to clinical successes and strategic alliances, allowing Neuren to balance the speculative nature of biotech investments with the promise of transformative medical breakthroughs.

NEU Intrinsic Value
HIDDEN
Show

See Also

What is Neuren Pharmaceuticals Ltd's Accounts Payable?
Accounts Payable
6.7m AUD

Based on the financial report for Jun 30, 2025, Neuren Pharmaceuticals Ltd's Accounts Payable amounts to 6.7m AUD.

What is Neuren Pharmaceuticals Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
7%

Over the last year, the Accounts Payable growth was 49%. The average annual Accounts Payable growth rates for Neuren Pharmaceuticals Ltd have been 83% over the past three years , 62% over the past five years , and 7% over the past ten years .

Back to Top